Citations

Clear

4847 citation(s) found for "Tu, Eric".

[P‐121]: Resting FDG‐PET in neurologically normal individuals reporting dream enactment behavior: Preclinical dementia with lewy bodies?
Caselli, Richard J. , Reiman, Eric M. , Alexander, Gene E. , Osborne, David, Parish, James M., Krahn, Lois E., Chen, Kewei , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_2 | Pages: No page available

10.1016/j.jalz.2005.06.194 Get It

Preserving Olfactory Function in Anterior Craniofacial Surgery through Cribriform Plate Osteotomy Applied in Selected Patients
Feiz‐Erfan, Iman , Han, Patrick P., Spetzler, Robert F., Horn, Eric M., Klopfenstein, Jeffrey D., Kim, Louis J. , Porter, Randall W., Beals, Stephen P., Lettieri, Salvatore C. , Joganic, Edward F., Kim, Louis J.

Mayo Clinic

Operative Neurosurgery | July 13, 2005 | Volume: 57 | Issue: suppl_1 | Pages: 86-93

10.1227/01.neu.0000163487.94463.4a | PMID 15987573 Get It

AbstractOBJECTIVE:Olfaction is often sacrificed to gain access to the cranial base in anterior craniofacial surgery. We describe the long-term results of olfactory function in patients who underwent anterior craniofacial surgery and a cribriform plate osteotomy to preserve olfaction.METHODS:Between 1992 and 2004, 28 patients underwent 29 cribriform plate osteotomies in an attempt to preserve olfaction during anterior craniofacial surgery performed through modified extended transbasal approaches. Patients' charts and office notes were reviewed retrospectively. Formal olfactory testing was available in 5 patients, but most data were based on patients' subjective reports of olfaction. Olfactory preservation was defined by the subjective ability to detect fumes such as coffee, chocolate, roses, and orange juice regardless of the intensity of the sensation. Follow-up was based on phone calls to patients.RESULTS:Four patients were lost to follow-up and excluded. Therefore, follow-up was available in 24 patients after 25 procedures. On the basis of patients' subjective reports, olfaction was spared in 22 patients after 23 procedures (92%) and was confirmed objectively in the five patients formally tested. After surgery, only two patients were anosmic.CONCLUSION:Olfaction can be preserved in selected patients undergoing anterior craniofacial surgery. At least 1 cm of nasal mucosa should remain attached to the cribriform plate, which can be achieved by including the nasal bone in the osteotomy of the orbital bar. A medial orbital canthopexy is therefore necessary after these procedures.
Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism
Reiman, Eric M. , Chen, Kewei , Alexander, Gene E. , Caselli, Richard J. , Bandy, Daniel, Osborne, David, Saunders, Ann M. , Hardy, John , Hardy, John

Mayo Clinic

Proceedings of the National Academy of Sciences | June 2, 2005 | Volume: 102 | Issue: 23 | Pages: 8299-8302

10.1073/pnas.0500579102 | PMID 15932949 Get It

Patients with Alzheimer's disease (AD) have abnormally low positron emission tomography (PET) measurements of the cerebral metabolic rate for glucose (CMRgl) in regions of the precuneus and the posterior cingulate, parietotemporal, and frontal cortex. Apolipoprotein E (APOE) ε4 gene dose (i.e., the number of ε4 alleles in a person's APOE genotype) is associated with a higher risk of AD and a younger age at dementia onset. We previously found that cognitively normal late-middle-aged APOE ε4 carriers have abnormally low CMRgl in the same brain regions as patients with probable Alzheimer's dementia. In a PET study of 160 cognitively normal subjects 47–68 years of age, including 36 ε4 homozygotes, 46 heterozygotes, and 78 ε4 noncarriers who were individually matched for their gender, age, and educational level, we now find that ε4 gene dose is correlated with lower CMRgl in each of these brain regions. This study raises the possibility of using PET as a quantitative presymptomatic endophenotype to help evaluate the individual and aggregate effects of putative genetic and nongenetic modifiers of AD risk.
Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography
Wiseman, Gregory A., Ritchie, Justine M., Menda, Yusuf , Wooldridge, James E. , Mottaghy, Felix M. , Rohren, Eric , Blumstein, Norbert M., Stolpen, Alan H. , Link, Brian K. , Reske, Sven N., Graham, Michael M. , Cheson, Bruce D. , Juweid, Malik E. , Vose, Julie M. , Link, Brian K , Menda, Yusuf

Mayo Clinic

Journal of Clinical Oncology | April 19, 2005 | Volume: 23 | Issue: 21 | Pages: 4652-4661

10.1200/jco.2005.01.891 | PMID 15837965 Get It

Purpose To determine whether a response classification based on integration of fluorine-18–fluorodeoxyglucose positron emission tomography (FDG-PET) into the International Workshop Criteria (IWC) provides a more accurate response assessment than IWC alone in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods Fifty-four patients with aggressive NHL who underwent FDG-PET and computed tomography 1 to 16 weeks after four to eight cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone were assessed for complete response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD), and progressive disease (PD) by the IWC and by integrated IWC and FDG-PET (IWC+PET). Progression-free survival (PFS) was also compared between IWC- and IWC+PET-assigned response designations. Results By IWC, 17 patients had a CR, seven had a CRu, 19 had a PR, nine had SD, and two had PD. In comparison, by IWC+PET, 35 patients had a CR, 12 had a PR, six had SD, one had PD, and zero had a CRu. In separate multivariate models, PFS was significantly shorter in patients with PR than in those with a CR using IWC (hazard ratio [HR], 8.9; P = .021) or IWC+PET (HR, 29.7; P = .0003). However, when the two classifications were included in the same multivariate model, only IWC+PET was a statistically significant independent predictor for PFS (P = .008 v P = .72 for IWC). In addition, when patients with a PR by IWC and a CR by IWC+PET were compared with those with a CR by IWC and a CR by IWC+PET, there was no significant difference in PFS (HR, 1.6; P = .72), indicating that IWC+PET identified a subset of IWC-PR patients with a more favorable prognosis. Conclusion Compared with IWC, the IWC+PET-based assessment provides a more accurate response classification in patients with aggressive NHL.
Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering
Vanegas, Maria, Llano, Manuel , Delgado, Sharon, Thompson, Daniah, Peretz, Mary, Poeschla, Eric M.

Mayo Clinic

Journal of Cell Science | March 30, 2005 | Volume: 118 | Issue: 8 | Pages: 1733-1743

10.1242/jcs.02299 | PMID 15797927 Get It

To investigate the basis for the LEDGF/p75 dependence of HIV-1 integrase (IN) nuclear localization and chromatin association, we used cell lines made stably deficient in endogenous LEDGF/p75 by RNAi to analyze determinants of its location in cells and its ability to interact with IN. Deletion of C-terminal LEDGF/p75 residues 340-417 preserved nuclear and chromatin localization but abolished the interaction with IN and the tethering of IN to chromatin. Transfer of this IN-binding domain (IBD) was sufficient to confer HIV-1 IN interaction to GFP. HRP-2, the only other human protein with an identifiable IBD domain, was found to translocate IN to the nucleus of LEDGF/p75(–) cells. However, in contrast to LEDGF/p75, HRP-2 is not chromatin bound and does not tether IN to chromatin. A single classical nuclear localization signal (NLS) in the LEDGF/p75 N-terminal region (146RRGRKRKAEKQ156) was found by deletion mapping and was shown to be transferable to pyruvate kinase. Four central basic residues in the NLS are critical for its activity. Strikingly, however, stable expression studies with NLS(+/–) and IBD(+/–) mutants revealed that the NLS, although responsible for LEDGF/p75 nuclear import, is dispensable for stable, constitutive nuclear association of LEDGF/p75 and IN. Both wild-type LEDGF/p75 and NLS-mutant LEDGF/p75 remain entirely chromatin associated throughout the cell cycle, and each tethers IN to chromatin. Thus, these experiments reveal stable nuclear sequestration of a transcriptional regulator by chromatin during the nuclear-cytosolic mixing of cell division, which additionally enables stable tethering of IN to chromatin. LEDGF/p75 is a multidomain adaptor protein that interacts with the nuclear import apparatus, lentiviral IN proteins and chromatin by means of an NLS, an IBD and additional chromatin-interacting domains.
Human Catecholamine Sulfotransferase (SULT1A3) Pharmacogenetics: Common Functional Genetic Polymorphism in African‐American Subjects
Thomae, Bianca A., Rifki, Oktay F., Theobald, Michelle A., Eckloff, Bruce W., Wieben, Eric D. , Weinshilboum, R. M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90462-0 Get It

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
Genomic Susceptibility Loci for Brain Atrophy in Hypertensive Sibships From the GENOA Study
Fornage, Myriam , Jack, Clifford R. , Kardia, Sharon L. R., Boerwinkle, Eric , Turner, Stephen T. , Mosley, Thomas H. , Andrade, Mariza de , Jack, Clifford R

Mayo Clinic

Hypertension | February 8, 2005 | Volume: 45 | Issue: 4 | Pages: 793-798

10.1161/01.hyp.0000154685.54766.2d | PMID 15699467 Get It

We measured 366 microsatellite markers genome-wide to search for loci contributing to subcortical white matter ischemic damage (leukoariosis) and brain atrophy in 488 non-Hispanic white subjects (193 men, 295 women; mean age±SD=64.1±7.7 years; 79% hypertensive) from 223 sibships recruited through ≥2 members with essential hypertension diagnosed before age 60. Leukoariosis was quantitated by magnetic resonance imaging (MRI), brain atrophy by the difference between intracranial and brain volumes, and calculated mean arterial pressure and pulse pressure provided measures of steady-state level and pulsatile components of blood pressure. After adjustment for sex and age, variance components models estimated significant heritability of leukoariosis (0.72), brain atrophy (0.52), mean arterial pressure (0.084), and pulse pressure (0.294) ( P <0.0001 for each trait). Univariate maximum logarithm of odds scores (MLS) were observed for leukoariosis on chromosome 5 (MLS=1.91; P =0.00150); for brain atrophy on 1q and 17p (MLS=2.76, P =0.00018); for mean arterial pressure on 11p (MLS=1.57; P =0.00354); and for pulse pressure on 11p (MLS=3.02; P =0.00070). Bivariate linkage analyses provided evidence of loci with pleiotropic effects on brain atrophy and pulse pressure on chromosomes 11p (MLS = 5.07 at 16 cM; P =0.00001) and 16q (MLS of 4.56 at 124 cM; P =0.00003). These results demonstrate usefulness of multivariate linkage analyses to detect loci with pleiotropic effects on genetically correlated traits and suggest overlap between the genes influencing blood pressure and those contributing to brain atrophy.
Rationale and study design of the CardioGene Study: genomics of in-stent restenosis
Ganesh, Santhi K. , Skelding, Kimberly A., Mehta, Laxmi S. , O’Neill, Kathleen , Joo, Jungnam , Zheng, Gang , Goldstein, James, Simari, Robert A., Billings, Eric M. , Geller, Nancy L. , Holmes, David R. , Nabel, Elizabeth G., O’Neill, William W. , Mehta, Laxmi

Mayo Clinic

Pharmacogenomics | October 18, 2004 | Volume: 5 | Issue: 7 | Pages: 949-1004

10.1517/14622416.5.7.949 | PMID 15469413 Get It

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
Rinehart, John J., Adjei, Alex A. , LoRusso, Patricia , Hecht, J. Randolph , Natale, Ronald B., Hamid, Oday , Varterasian, Mary , Asbury, Peggy, Kaldjian, Eric, Gulyas, Stephen, Mitchell, David, Herrera, Román, Chan, Anthony T.�C. , Waterhouse, David , Sebolt–Leopold, Judith S. , Meyer, Mark B.

Mayo Clinic

Journal of Clinical Oncology | October 14, 2004 | Volume: 22 | Issue: 22 | Pages: 4456-4462

10.1200/jco.2004.01.185 | PMID 15483017 Get It

Purpose This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer. Patients and Methods Patients with advanced colorectal, NSCLC, breast, or pancreatic cancer received oral CI-1040 continuously at 800 mg bid. All patients had measurable disease at baseline, a performance status of 2 or less, and adequate bone marrow, liver, and renal function. Expression of pERK, pAkt, and Ki-67 was assessed in archived tumor specimens by quantitative immunohistochemistry. Results Sixty-seven patients with breast (n = 14), colon (n = 20), NSCLC (n = 18), and pancreatic (n = 15) cancer received a total of 194 courses of treatment (median, 2.0 courses; range, one to 14 courses). No complete or partial responses were observed. Stable disease (SD) lasting a median of 4.4 months (range, 4 to 18 months) was confirmed in eight patients (one breast, two colon, two pancreas, and three NSCLC patients). Treatment was well tolerated, with 81% of patients experiencing toxicities of grade 2 or less severity. Most common toxicities included diarrhea, nausea, asthenia, and rash. A mild association (P < .055) between baseline pERK expression in archived tumor specimens and SD was observed. Conclusion CI-1040 was generally well tolerated but demonstrated insufficient antitumor activity to warrant further development in the four tumors tested. PD 0325901, a second generation MEK inhibitor, has recently entered clinical development and, with significantly improved pharmacologic and pharmaceutical properties compared with CI-1040, it may better test the therapeutic potential of MEK inhibition in cancer.
Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the β-Blocker Evaluation of Survival Trial
Krause‐Steinrauf, Heidi , Nuzzo, Rebecca, Liang, Chang‐seng , Lowes, Brian D. , Hattler, Brack , Abraham, William T. , Olson, L., Krueger, Steven K. , Thaneemit-Chen, Surai, Hare, John, Loeb, Henry S., Domański, Mikołaj , Eichhorn, Eric J., Zelis, Robert, Lavori, Philip W., Bristow, Michael R. , Lindenfeld, JoAnn

Mayo Clinic

Circulation | August 31, 2004 | Volume: 110 | Issue: 11 | Pages: 1437-1442

10.1161/01.cir.0000141297.50027.a4 | PMID 15337700 Get It

Background— Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results— Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant ( P <0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group-dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions— In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.